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Cyclosporine is a substrate of cytochrome P-450 3A (CYP3A)
subfamily of enzymes and characterized by a narrow
therapeutic range with wide interindividual variation in
pharmacokinetics. A few single-nucleotide polymorphisms
detected in CYP3A genes have been shown to correlate
significantly with the CYP3A protein expression and activity.
We therefore postulated that these polymorphisms could be
responsible for some of the interindividual variation in
cyclosporine pharmacokinetics. The objective of our study is
to determine correlation if any between single-nucleotide
polymorphisms of CYP3A5 and CYP3AP1 on cyclosporine dose
requirement and concentration-to-dose ratio in renal allograft
recipients. Cyclosporine-dependent renal allograft recipients
were genotyped for CYP3A5 A6986G and CYP3AP1 G-44A. The
cyclosporine dosages prescribed and the corresponding
cyclosporine trough levels for each patient were recorded so
that cyclosporine dose per weight (mg/kg/day) and
concentration-to-dose ratio (C0/D, whereby C0 is trough level
and D is daily dose per weight) could be calculated. A total of
67 patients were recruited for our study. The dose
requirement for 1, 3, and 6 months post-transplantation
ranged 2.3–11.4, 1.0–9.0, and 1.4–7.2 mg/kg/day, respectively.
Patients with *1*1*1*1 (n¼ 5) CYP3A5- and CYP3AP1-linked
genotypes needed higher dose of cyclosporine compared to
patients with *1*3*1*3 (n¼ 27) and *3*3*3*3 (n¼ 33) linked
genotypes in months 3 and 6 post-transplantation (Po0.016).
The identification of patients with *1*1*1*1 by CYP3A5 and
CYP3AP1 genotyping may have a clinically significant and
positive impact on patient outcome with reduced rejection
rate by providing pretransplant pharmacogenetic information
for optimization of cyclosporine A dosing.
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The introduction of cyclosporine A (CsA), which is a
calcineurin inhibitor, resulted in substantial progress in solid
organ transplantation. CsA is used to prevent allograft
rejection after solid organ transplantation. It is, however,
characterized by a narrow therapeutic range and highly
variable pharmacokinetics. Therefore, CsA daily doses must
be adjusted to whole-blood CsA concentrations to improve
the efficacy and reduce the toxicity of CsA treatment. CsA is
dosed according to blood concentrations, and the parameter
most widely used for therapeutic drug monitoring is the
predose or trough concentration (C0).
Therapeutic drug monitoring of CsA reveals a large
interindividual variability in the oral dose required to achieve
target blood concentrations. Kahan et al.1 showed the
association between chronic rejection incidence and indivi-
dual pharmacokinetic parameters in which 27% of total risk
of chronic rejection could be explained by greater than 20%
variation in steady-state CsA concentration. It is widely
recognized that chronic rejection is a main cause of graft
failure, although its pathogenesis is poorly understood.2
There are many factors that contribute to the variability of
CsA pharmacokinetics such as age, gender, and race,
concomitant diseases, and drug–drug interaction.3 CsA is
extensively metabolized by the cytochrome P-450 3A
(CYP3A) subfamily of enzymes, with less than 1% of the
administrated dose excreted as parent drug.4 Interindividual
heterogeneity in the expression of CYP3A enzymes have,
therefore, been suspected to be a factor that results in
variation of CsA pharmacokinetics variation.
CYP3A enzymes are responsible for the metabolism of
many drugs, including cyclosporine, tacrolimus, HIV pro-
tease inhibitors, and midazolam.5,6 Human CYP3A activities
reflect the expression of isoenzymes CYP3A4, CYP3A5,
CYP3A7, and CYP3A43.7–11 CYP3A4 is the dominant CYP3A
enzyme in the human liver and small intestine.12–14 CYP3A5
is widely considered as the second most important CYP3A
protein in human liver and intestine. However, it was found
to be the primary CYP3A family member expressed in
kidney, lung, prostate, breast, and polynuclear leucocytes,
and was postulated to have important physiological function
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in these tissues.15,16 CYP3A5 expression is clearly poly-
morphic, with individuals exhibiting a relatively high or low
level of protein.7,17–19 CYP3A7 is mainly expressed during
fetal life and is significantly downregulated after birth.20 The
existence of CYP3A43 has been recently reported, but its
relative contribution to drug metabolism remain unclear.
There have been recent reports of the existence of two
pseudogenes, CYP3AP1 and CYP3AP2.21 Previously, a
mutation, A-44G, was believed to have been present in the
CYP3A5 promoter and this was found to correlate with the
expression of CYP3A5.22 Sequencing of CYP3A locus,
however, reveals that this polymorphism is actually present
in the promoter of CYP3AP1.21
Kuehl et al. reported that an A6986G transition within
intron 3 of CYP3A5 correlated well with the expression of
CYP3A5. The replacement of A nucleotide (CYP3A5*1) by G
nucleotide (CYP3A5*3) at 6986 locus creates an alternative
splice site in the pre-mRNA. This causes the production of
aberrant mRNA that contains 131 bp of intron 3 sequence
(exon 3B) inserted between exon 3 and exon 4.15,17 Lin
et al.18 reported that the mean CYP3A5*1 mRNA level is
four-fold higher in CYP3A5*1/*3 livers compared to
CYP3A5*3/*3 livers whereas CYP3A5*3 mRNA was com-
pletely absent in CYP3A5*1/*1 livers. Studies have confirmed
that CYP3A5*3/*3 genotype was perfectly associated with low
hepatic CYP3A5 protein content in different ethnic popula-
tions.17,23 As such, CYP3A5 A6986G polymorphism is postu-
lated to influence the pharmacokinetics of its substrates.
CYP3AP1 A-44G polymorphism was found to be in strong
linkage disequilibrium with CYP3A5 A6986G. Most people
who has A-44 (CYP3AP1*3) also has CYP3A5*3, which
encodes a relatively small amount of functioning mRNA. The
CYP3A5 mRNA content is greater in people with a G-44
(CYP3AP1*1) allele than those people who are homozygous
for A-44 (CYP3AP1*3).17
As cyclosporine is extensively metabolized by CYP3A5
enzyme, we therefore postulated that CYP3A5 A6986G
polymorphism as well as the strongly linked CYP3AP1
G-44A polymorphism may influence the required cyclo-
sporine dose and concentration-to-dose ratio (C0/D) in renal
transplant recipients.
RESULTS
Subject population
A total of 73 renal allograft recipients were recruited for the
study. Six out of the 73 patients were later excluded from the
study, four of whom were on diltiazem, one was involved in
another medication study and the remaining one patient had
stopped taking CsA 2 months after transplantation. Among
the 67 patients, 57 of them have complete immunosuppres-
sive medication records for 6 months post-transplantation.
Interindividual variation in CsA dose requirement and C0/D
ratio
The targeted dose requirement for 1 (n¼ 59), 3 (n¼ 66) and
6 (n¼ 66) months post-transplantation ranged from 2.3 to
11.4, 1.0 to 9.0, and 1.4 to 7.2 mg/kg/day, respectively. The 1,
3, and 6 months post-transplantation concentration/dose
ratio ranged from 25.9 to 115.5, 24.4 to 163.3, and 32.4 to
237.2, respectively. The broad ranges of dose requirement and
C0/D ratio confirmed the wide interindividual variation in
CsA metabolism.
CYP3A5 and CYP3AP1 genotyping and linkage
disequilibrium
Table 1 showed the frequency of CYP3A5 A6986G and
CYP3AP1 G-44A genotype of renal transplant recipients. The
genotype frequencies were not significantly different from the
Hardy–Weinberg equation. We found that 97% (65 out of 67
patients) had completely linked CYP3A5 A6986G and
CYP3AP1 G-44A genotype, in which five out of six patients
with homozygous CYP3A5*1, also had CYP3AP1*1*1
genotype. Out of 27 patients, 26 were heterozygous for both
single-nucleotide polymorphisms, and all patients who were
homozygous for 3A5*3 were also homozygous for the
CYP3AP1*3 genotype. This confirms the strong linkage
disequilibrium between CYP3A5 A6986G and CYP3AP1
G-44A polymorphisms.
CYP3A linked genotype and CsA dose requirement and C0/D
ratio interaction
Samples were grouped according to CYP3A5 (*1*1_ _) and
CYP3AP1 (_ _ *1*1) genotypes. In comparing the genotypes,
homozygous *1 (*1*1*1*1) in both CYP3A5 and CYP3AP1
gene was chosen as reference genotype to compare with
others. This genotype would be predicted to have the highest
P450 3A enzyme activity, and thus would be associated with
the highest dose requirement and the lowest C0/D ratio of
CsA. The present study showed that patients with reference
genotype have significantly higher dose requirement of CsA
compared to patient with heterozygous *1*3 (*1*3*1*3)
genotypes in 1, 3, and 6 months (P¼ 0.033, 0.006, and 0.010,
respectively) post-transplantation (Table 2 and Figure 1).
Comparison between reference genotype and homozygous *3
(*3*3*3*3) genotypes reveals that patients with homozygous
*3 genotype have lower dose requirement of CsA in 1
(P¼ 0.138), 3 (P¼ 0.016), and 6 (P¼ 0.005) months.
However, there is no significant difference in concentration/
dose ratio of CsA among the patients. Gene–dose effect was
not observed in our study as there is no significant difference
in CsA dose requirement and concentration/dose ratio
between genotypes *1*3*1*3 and *3*3*3*3. We have excluded
Table 1 | Frequencies of CYP3A5, CYP3AP1, and linked
genotypes in the renal allograft recipients population
CYP3AP1
G-44A
CYP3A5 A6896G genotype
genotype *1*1 *1*3 *3*3 Total
*1*1 0.075 (n=5) 0.015 (n=1) 0 (n=0) 0.090 (n=6)
*1*3 0.015 (n=1) 0.388 (n=26) 0 (n=0) 0.403 (n=27)
*3*3 0 (n=0) 0 (n=0) 0.507 (n=34) 0.507 (n=34)
Total 0.090 (n=6) 0.403 (n=27) 0.507 (n=34) 1 (n=67)
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*1*1*1*3 and *1*3*1*1 genotypes from analysis as we have
only one patient in each of the genotype group.
CYP3A linked genotype influence on transplantation
outcome
Among the 67 patients, 14 (20.9%) had experienced at least
one acute rejection episode within 6 months post-transplanta-
tion. Sixty-one (91.0%) of the patients were on anti-
hypertensive treatment at month 6 post-transplantation.
The average serum creatinine levels of the patients at the end
of months 6 (n¼ 67), 12 (n¼ 63), and 36 (n¼ 44) post-
transplantation were 130.5741.10, 124.3735.00, and
136.6754.15 mmol/l, respectively. No significant correlation
was detected between CYP3A linked genotype and trans-
plantation outcome data based on acute rejection rates,
hypertension, or serum creatinine levels.
Influence of ethnicity
Previous studies have shown that ethnicity may contribute to
the variation in the pharmacokinetics of CsA.24–26 Dunn et al.
have demonstrated that the ethnic origin of transplant
recipients is an important factor in graft survival, with a
pattern of reduced graft survival secondary to chronic
rejection in black recipients.27,28 The influence of ethnicity
has been supported by the first report of recipients of non-
Caucasoid populations, which includes Mediterranean/Cen-
tral Asians and Afro-Caribbean/Eastern Asians, and these
groups of patients were found to have significantly higher
incidence of chronic rejection compared to Northern and
Southern European populations.28 From the present study,
Indian ethnic group has a lower CsA dose requirement and
higher C0/D ratio compared to both Malay and Chinese
throughout the 6 months post-transplantation (Table 3).
However, the differences are not statistically significant.
Interpretation of the influence of ethnicity in our study is
Table 2 | The influence of CYP3A5- and CYP3AP1-linked genotypes on CsA dose requirement and C0/D ratio for All Patients and
Chinese Patients cohorts at the end of months 1, 3, and 6 after transplantation
No. of months post-transplantation
1 3 6
Cohort
CYP3A5 and
CYP3AP1 genotype n
Dose (mg/
day/kg) C0/D ratio n
Dose (mg/
day/kg) C0/D ratio n
Dose (mg/
day/kg) C0/D ratio
All patients *1*1*1*1 5 7.971.44 49.5710.54 5 6.771.52 49.4715.79 5 5.271.24 54.9713.41
*1*1*1*3 1 6.7 96.9 1 3.0 96.2 1 2.3 114.3
*1*3*1*1 0 — — 1 3.6 58.5 1 4.5 45.2
*1*3*1*3 24 5.971.90 66.0719.19 26 4.771.45 67.8720.90 26 3.571.06 65.8720.60
*3*3*3*3 29 6.971.75 59.7719.39 33 4.671.32 63.6724.38 33 3.771.18 70.7744.62
Chinese
patients
*1*1*1*1 3 7.371.53 50.1714.76 3 6.872.14 49.7722.32 3 5.571.60 51.7717.88
*1*1*1*3 0 — — 0 — — 0 — —
*1*3*1*1 0 — — 0 — — 0 — —
*1*3*1*3 18 6.371.80 62.4717.69 20 4.871.29 69.1720.69 20 3.771.11 61.0717.63
*3*3*3*3 25 6.971.87 60.3720.69 28 4.771.50 60.2724.78 29 3.771.23 69.8747.35
Graphical illustration of tabulated results together with P-values is shown in Figure 1.
CsA, cyclosporine A.
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Figure 1 | Cyclosporine dose requirements in relation to CYP3A5
and CYP3AP1 linked genotypes at months 1, 3, and 6
post-transplantation in 67 renal allograft recipients. (a) All
Patients, significant differences in CsA dose requirement were
observed between patients with *1*1*1*1 and patients with
*1*3*1*3 or *3*3*3*3. (b) Chinese Patients, when Chinese
patients were analyzed separately, the difference in CsA dose
requirement persists at month 6 (P40.05).
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limited by the low sample sizes of Malay (n¼ 6, 9%) and
Indian (n¼ 6, 9%) compared to Chinese (n¼ 52, 77.6%).
We therefore performed analysis solely on the Chinese
population in order to eliminate the race factor in the
interpretation of influence on CsA dose requirement and
C0/D ratio by CYP3A5 A6896G and CYP3AP1 G-44A linked
polymorphisms. In months 3 post-transplantation, the
differences between *1*1*1*1 and *1*3*1*3 (P¼ 0.068) as
well as *1*1*1*1 and *3*3*3*3 (P¼ 0.071) were not
significant. However, the significant differences between the
linked genotype groups remained in month 6 post-trans-
plantation *1*1*1*1 versus *1*3*1*3 (P¼ 0.045) and
*1*1*1*1 versus *3*3*3*3 (P¼ 0.049).
Influence of gender
Study on demographic factors confirmed that gender has
significant effect on the pharmacokinetics of CsA.24 At
months 3 and 6 post-transplantation, male and female
recipients had significant difference in CsA dose requirement
(P¼ 0.042 and 0.015) and C0/D ratio (P¼ 0.002 and 0.001,
Table 3) with females needing more CsA to achieve the
desired concentration.
DISCUSSION
In the study on the impact of the variability of CsA trough
levels on long-term renal allograft function, Waiser et al.29
demonstrated that long-term graft survival in patients with
low mean CsA trough levels (o270 ng/ml) is reduced by an
increased incidence of acute rejection episodes as compared
to normal (270–370 ng/ml) or high mean CsA trough level
(4370 ng/ml) patients. In contrast, no difference was
observed in immunosuppressive effect between normal and
high mean CsA trough level groups. In addition, Soin et al.30
reported that CsA levels of 175 mg/l or more in the early post-
transplantation period (first 4 weeks after transplantation)
were found to reduce chronic rejection in liver transplant
recipients without any added renal or septic complications.
These results suggest that early detection of patients with
consistently low mean CsA trough level phenotypes is
important in the prevention of organ rejection.31
The impact of CYP3AP1 G-44A polymorphism on
tacrolimus dose requirement was first reported by Macphee
et al.31 and followed by Thervet et al.,32 who revealed that
tacrolimus concentration:dose ratio is correlated with the
CYP3A5 genotype. More recently, Thervet et al. finding was
supported by Hesselink et al.11 and Haufroid et al.33 G-44A
polymorphism occurs in the BTE element of CYP3AP1
pseudogene, and it was proposed that mutation at this site
may perturb Sp1 binding and result in reduced gene
transcription in individuals homozygous for the A-44
allele.15,22 In view of the fact that CYP3AP1 is a noncoding
gene, it is felt that CYP3AP1 G-44A polymorphism cannot be
responsible for polymorphic CYP3A5 expression. The
observation of a strong association between CYP3AP1
G-44A and protein expression of CYP3A5 subsequently led
Kuehl et al.17 to identify the polymorphism of A6986G in
intron 3 of CYP3A5 gene, which is in strong linkage
disequilibrium with CYP3AP1 G-44A as the dominant factor
driving CYP3A5 expression. In concordance with most of the
studies, our study confirm the strong linkage disequilibrium
between CYP3A5 A6986G and CYP3AP1 G-44A in which
97% of the patients in our study have completed linked
genotypes at these locations.
Like tacrolimus, CsA is a substrate for the CYP3A genes. It
was postulated that the CYP3A5 A6986G polymorphism may
contribute to the interindividual variation in the pharmaco-
kinetics of CsA. However, there are at least three studies that
reported no significant influence of CYP3A5 A6986G
polymorphism on CsA daily dose requirement and pharma-
cokinetics.11,34,35 The observation on CYP3A5 genotypes in
the present study is consistent with the previous find-
ings.11,34,35 Conflicting finding was reported by Haufroid
Table 3 | CsA dose requirement and C0/D ratio in relation to gender, race and type of transplantation at months 1, 3, and 6
after transplantation
1 3 6
No. of months
post-transplantation n
Dose
(mg/day/kg)
C0/D
ratio n
Dose
(mg/day/kg)
C0/D
ratio n
Dose
(mg/day/kg)
C0/D
ratio
Gender
Male 30 6.4771.81 65.4718.85 36 4.371.26a 72.6724.41b 35 3.370.95c 78.9741.82d
Female 29 6.871.91 58.5719.81 30 5.271.60a 55.0716.08b 31 4.271.31c 55.4718.57d
Race
Malay 6 6.672.23 55.076.48 6 4.671.46 59.1716.36 5 3.771.06 68.1711.27
Chinese 46 6.771.82 60.5719.10 51 4.971.51 63.0723.32 52 3.871.26 65.4737.27
Indian 4 5.972.48 80.5725.13 6 3.971.24 78.6720.77 6 3.171.04 87.4728.27
Other 3 6.471.33 75.1724.22 3 4.671.57 74.5722.00 3 3.070.51 71.2721.75
Type of transplantation
Live-related 24 7.371.8 64.7717.59 25 4.971.43 61.6717.19 26 3.971.19 68.8740.24
Live-non-related 4 5.572.36 76.1729.1 4 3.570.76 67.5726.6 3 3.270.96 79.1729.79
Cadeveric 31 6.271.70 58.1719.0 37 4.871.54 66.4725.73 37 3.671.24 66.3731.70
No significant difference was detected among the different groups of race and type of transplantation in CsA dose requirement and C0/D ratio. However, gender factor is
significantly correlated with dose requirement (aP=0.042; cP=0.015) and C0/D ratio (
bP=0.002; dP=0.001) of CsA at months 3 and 6 after transplantation.
CsA, cyclosporine A.
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et al.33 in which a small effect of CYP3A5*3 polymorphism
on trough level of CsA in relation to last dose of CsA taken
before blood sampling (C0/D ratio) was observed in 50 stable
renal transplant recipients.
Previously, Yates et al. reported that the oral cyclosporine
clearance was lower in CYP3A5 expressors compared to
nonexpressors. This unexpected observation was later
claimed as an artifact by the authors themselves as all of
the CYP3A5 nonexpressors in their study are also MDR
T3435 carriers.4 Indeed, they have shown an increase of CsA
oral clearance in MDR T3435 carriers compared to the non-
MDR T3435 carriers. This therefore prohibits the authors
from assessing the effect of CYP3A5 polymorphism on
cyclosporine pharmacokinetic parameters independently.4,32
In our study, approximately 40% of the *1*3*1*3 and
*3*3*3*3 linked genotype patients are MDR C3435 homo-
genous carriers. In addition, we did not observe any
significant correlation between MDR C3435T or MDR
G2677A/T or MDR C1236T and CsA dose requirements in
our study. The present study should be free of population
selection bias as the allele frequencies for both CYP3A5 and
CYP3AP1 were in Hardy–Weinberg equilibrium and were
consistent with our unpublished data (n¼ 334 healthy
volunteers). Therefore, the observed significant differences
in CsA dose requirement is possibly caused by CYP3A5 and
CYP3AP1 linked genotype polymorphisms. Studies suggest
that CsA area under concentration–time curve represents a
more reliable assessment of a patient’s exposure to drug and
has stronger correlation with the outcome of transplantation
as compared to CsA C0.
36–38 However, area under concen-
tration–time curve studies are not routinely performed in our
center, and therefore CsA C0 data were used in this study.
Unlike the observation made with tacrolimus, we did not
observe significant difference in CsA dose requirement
between *1*3*1*3 and *3*3*3*3 linked genotypes even
though previous studies have shown *1*3*1*3 is an expressor
genotype, which produces higher amount of functional
CYP3A5 protein compared to *3*3*3*3 nonexpressor
genotype. In addition, we did not find significant differences
in CsA C0/D ratio as observed with tacrolimus.
32
In conclusion, our study demonstrates that a significant
correlation exists between the CsA dose requirement and
CYP3A5 A6986G and CYP3AP1 G-44A linked genotypes in
months 3 and 6 post-transplantation. Patients with *1*1*1*1
linked genotype require significantly higher CsA dosage to
reach the target trough level compared to patients with
*1*3*1*3 or *3*3*3*3 linked genotypes. Our findings suggest
that patients with *1*1*1*1 linked genotype are likely to be
receive suboptimal doses of CsA using the standard
immunosuppression dosage regimen. They will therefore be
at higher risk of complications particularly with acute
rejection, which may adversely affect long-term graft survival.
Therefore, routine CYP3A5 and CYP3AP1 pretransplant
genotyping may have an important clinical role in the
individualization and optimization of CsA dosing of allograft
recipients.
MATERIALS AND METHODS
Patient population
Renal allograft recipients were recruited as subjects for this
retrospective study. All of the subjects received identical oral CsA
(NEORAL, Novartis Pharmaceuticals Corporation, Switzerland)
formulation as part of their immunosuppressive treatment. Patients
underwent cyclosporine therapeutic drug monitoring as per
University Malaya Medical Centre protocol. During routine visits,
blood samples were drawn from the patients for predose
cyclosporine level measurement and subsequent dosage of CsA
was prescribed according to the predose level and to the target
concentration. Patient demographic and biochemistry data are
shown in Table 4.
Immunosuppressive regimen
Immunosuppressive treatment of the patients consisted of a
combination of cyclosporine with azathioprine (or Cellcept) and
prednisolone. Newly transplanted recipients were started with CsA
8 mg/kg twice a day. Later, CsA administration was adjusted to target
trough level in the range of 350–450, 250–350, and 200–250mg/l for
months 1, 3, and 6 post-transplantation, respectively. Prednisolone
was administered according to a tapering schedule, which involved
20 mg prednisolone daily at the time of surgery, tapering by 2.5 mg
every 2 weeks to a maintenance dose of 5 mg daily. Patients taking
medication, which are known to interact with CsA, such as diltiazem
and fluconazole, were excluded from the study.
Data collection
Patient weight (kg) and daily dose (mg/day) of cyclosporine at the
end of months 1, 3, and 6 post-transplantation were recorded so that
cyclosporine dose per weight (mg/kg/day) could be calculated. CsA
Table 4 | The 67 renal allograft recipients’ demographic and
biochemistry data at the end of month 1 post-transplantation
Demographic factors N % of total
Gender
Male 36 53.7
Female 31 46.3
Race
Malay 6 9.0
Chinese 52 77.5
Indian 6 9.0
Other 3 4.5
Type of transplantation
Live-related 26 38.8
Live-non-related 4 6.0
Cadeveric 37 55.2
Mean7s.d.
Age (years) 38.5710.95
Follow-up period (days) 191.8715.3
Weight (kg) 61.8713.79
BMI (kg/m2) 23.678.51
Serum creatinine (mmol/l) 127.7738.44
Total bilirubin (mmol/l) 13.476.47
ALT activity (IU/l) 41.5717.25
AST activity (IU/l) 22.178.15
Hemoglobin (g/l) 118.5717.97
BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransfer-
ase.
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trough levels (C0) were assayed at approximately 12 h after the
previous dose by the Abbort CsA Monoclonal Whole Blood Reagent
Pack. Concentration (mg/l)-to-dose (mg/kg/day) ratio was calculated
by dividing the C0 by the corresponding daily dose of CsA. Mean
dose requirement and concentration/dose ratio were computed
from three sets of data (weight, daily dose, and C0) for each time
frame in order to reduce intraindividual variability.
Transplantation outcome on acute rejection rates, hypertension,
and serum creatinine level of each patient was studied. Acute
rejection within 6 months post-transplantation was analyzed and
based only on renal biopsy proven evidence of histological rejection.
In this study, hypertension was defined as the need for antihyper-
tensive treatment at month 6 post-transplantation. Serum creatinine
levels at the end of months 6, 12, and 36 post-transplantation were
recorded and analyzed.
Sample collection and DNA extraction
A measure of 10 ml of blood was collected from each subject into an
ethylenediaminetetraacetic acid containing vacutainer tube. DNA
was extracted from peripheral leucocytes by an improved salting out
method. DNA extracts were kept at 21C for long-term storage, and
41C for short-term storage.39
Molecular typing
The molecular typing of CYP3A5 A6986G and CYP3AP1 A-44G
alleles was performed by polymerase chain reaction (PCR)-
restriction fragment length polymorphism approach as described
by van Schaik et al.39 and Macphee et al.,31 respectively, with
some modifications. The primer sequences for CYP3A5 A6986G
(Forward: 50-CATGACTTAGTAGACAGATGA-30 and Reverse:
50-GGTCCAAACAGGGAAGAAATA-30) were designed to amplify
293 bp fragment of CYP3A5, whereas amplification of CYP3AP1
A-44G with forward primer 50-GGGGATGGATTTCAAGTATTCTG-30
and reverse primer 50-GTCCATCGCCACTTGCCTTCT-30 yields
391 bp fragment of CYP3AP1. The 25 ml of reaction mixture for
PCR amplification consisted of 1.5 mM MgCl2, 0.2 mM dNTPs mix,
10 PCR buffer, 1 U Taq polymerase, 0.3mM of each primer set,
100 ng of template DNA, and sterile distilled water. PCR was
performed in a MJ Research Thermalcycler (PTJ 200). Cycling
parameters were initial denaturation at 951C for 5 min, denaturation
at 941C for 30 s, annealing at 551C (CYP3A5 A6986G) or at 571C
(CYP3AP1 A-44G) for 30 s, extension at 721C for 1 min, and a final
extension step at 721C for 2 min, number of cycles were 35.
Of 25 ml PCR product, 8 ml was electrophoresed to ensure PCR
amplification successful in every PCR tube as indicated by the
presence of targeted DNA fragment in 2% agarose gel containing
ethidium bromide. The remaining PCR products (17 ml) were
digested with 10 U SspI (CYP3A5 A6986G) or AciI (CYP3AP1 A-
44G) restriction enzyme at 371C overnight to ensure complete
digestion. The DNA fragments were electrophoresed in 2% agarose
gel containing ethidium bromide. Bands were then detected by a
short wavelength UV transluminator.
SspI digestion of 293 bp CYP3A5 fragment yielded fragments of
148 and 125, 20 bp for A6986 (CYP3A5*1) allele and 168, 125bp for
G6986 (CYP3A5*3). For the CYP3AP1, the presence of G nucleotide
at 44 creates a restriction site of AciI, which gave 237, 154 bp
fragments after enzyme incubation.
Ethics
Ethics approval for this study was obtained from the Medical Ethics
Committee, University Malaya Medical Centre. Informed consent
was obtained from every subject.
Statistical analysis
SPSS version 12 software was used for statistical analysis. The
CYP3A5 and CYP3AP1 genotypes of subjects were used as
categorical independent variables. C0/D ratio and daily dose of
CsA required to achieve target trough level between two groups were
compared using the Mann–Whitney U test. P-values less than 0.05
were considered significant.
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